<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Ann Med Surg (Lond)</journal-id><journal-id journal-id-type="iso-abbrev">Ann Med Surg (Lond)</journal-id><journal-id journal-id-type="publisher-id">MS9</journal-id><journal-title-group><journal-title>Annals of Medicine and Surgery</journal-title></journal-title-group><issn pub-type="epub">2049-0801</issn><publisher><publisher-name>Lippincott Williams &#x00026; Wilkins</publisher-name><publisher-loc>Hagerstown, MD</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40109599</article-id><article-id pub-id-type="pmc">PMC11918727</article-id>
<article-id pub-id-type="publisher-id">AMSU-D-24-01804</article-id><article-id pub-id-type="doi">10.1097/MS9.0000000000002774</article-id><article-id pub-id-type="art-access-id">00003</article-id><article-version vocab="JAV" vocab-identifier="http://www.niso.org/publications/rp/RP-8-2008.pdf" article-version-type="Version of Record">3</article-version><article-categories><subj-group subj-group-type="heading"><subject>Editorial</subject></subj-group></article-categories><title-group><article-title>The potential of tirofiban: recommendation for further research on preventing early neurological deterioration in acute ischemic stroke</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Moghib</surname><given-names>Khaled A.</given-names></name><degrees>MBBS</degrees><email>Khaled-Ab-Maghib@students.kasralainy.edu.eg</email><xref rid="aff1" ref-type="aff">
<sup>a</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>b</sup>
</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Salomon</surname><given-names>IZERE</given-names></name><degrees>MBBS</degrees><email>izesajw73@gmail.com</email><xref rid="aff3" ref-type="aff">
<sup>c</sup>
</xref><xref rid="COR0001" ref-type="corresp">*</xref></contrib><aff id="aff1"><label>a</label>Faculty of Medicine, Cairo University, Cairo, Egypt</aff><aff id="aff2"><label>b</label>Medical Research Group of Egypt, Negida Academy, Arlington, MA, USA</aff><aff id="aff3"><label>c</label>University of Rwanda College of Medicine and Health Sciences, Kigali, Rwanda</aff></contrib-group><author-notes><corresp id="COR0001"><label>*</label>Corresponding author. Address: IZERE Salomon, University of Rwanda, College of Medicine and Health Sciences, Kigali, Rwanda. Tel.: +250 782067921. E-mail: <email>izesajw73@gmail.com</email> (I. Salomon).</corresp></author-notes><pub-date pub-type="collection"><month>1</month><year>2025</year></pub-date><pub-date pub-type="epub"><day>09</day><month>1</month><year>2025</year></pub-date><volume>87</volume><issue>1</issue><fpage>10</fpage><lpage>10</lpage><history><date date-type="received"><day>28</day><month>8</month><year>2024</year></date><date date-type="accepted"><day>16</day><month>11</month><year>2024</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2025 The Author(s). Published by Wolters Kluwer Health, Inc.</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article distributed under the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License 4.0</ext-link> (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri xlink:href="ms9-87-010.pdf"/><custom-meta-group><custom-meta><meta-name>OPEN-ACCESS</meta-name><meta-value>TRUE</meta-value></custom-meta></custom-meta-group></article-meta></front><body><p><italic toggle="yes">Dear Editor</italic>,</p><p>The recent article by Zhao et al. (2024) on the administration of intravenous (IV) tirofiban in patients with acute ischemic stroke (AIS) demonstrated a high safety profile and significantly improved the prognosis of early neurological deterioration. I commend the authors for conducting this critical study, which adds to the growing body of evidence on the role of antiplatelet therapy in AIS patients. The decision to administer IV tirofiban according to the well-established PRISM-PLUS protocol (well-established protocol for administering intravenous tirofiban) is prudent, as previous studies have demonstrated the relative safety of this approach. The rationale for continuing the infusion for 72&#x000a0;h to cover the high-risk window for neurological deterioration is well justified. However, the study&#x02019;s open-label design raises some methodological concerns, as a double-blinded medication administration would have been feasible and may have minimized potential bias. While the findings are promising, the authors acknowledge several limitations that warrant further investigation. Specifically, the generalization of results to patients with cardioembolic stroke and other global populations is unclear. Furthermore, the safety and efficacy of IV tirofiban in AIS patients with National Institutes of Health Stroke Scale scores outside the studied range of 4-20 remains to be determined. A search of recent randomized controlled trials revealed limited studies in this area, with fewer than 4 relevant results on PubMed. Future research should aim to address these gaps by expanding the study population to include a broader range of stroke subtypes and neurological deficits. Critical endpoints, such as functional outcomes (e.g., modified Rankin Scale scores) and the incidence of hemorrhagic complications, should be considered. Comparative studies between IV tirofiban and other antiplatelet or antithrombotic therapies would also help elucidate the relative benefits of this approach<sup>[<xref rid="R1" ref-type="bibr">1</xref>]</sup>.</p></body><back><fn-group><fn fn-type="equal"><p>Published online 9 January 2025</p></fn></fn-group><sec><title>Ethical approval</title><p>Not applicable.</p></sec><sec><title>Consent</title><p>Not required.</p></sec><sec><title>Sources of funding</title><p>No funds, grants, or other support were received.</p></sec><sec><title>Author contribution</title><p>All authors contributed equally.</p></sec><sec sec-type="COI-statement"><title>Conflict of interest disclosure</title><p>All the authors declare to have no conflicts of interest relevant to this study.</p></sec><sec><title>Research registration unique identifying number (UIN)</title><p>Not applicable.</p></sec><sec><title>Guarantor</title><p>All authors.</p></sec><sec sec-type="data-availability"><title>Data availability statement</title><p>Not applicable.</p></sec><sec><title>Provenance and peer review</title><p>Complete.</p></sec><ref-list><title>Reference</title><ref id="R1"><label>[1]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>W</given-names></name>
<name><surname>Li</surname><given-names>S</given-names></name>
<name><surname>Li</surname><given-names>C</given-names></name><etal/></person-group>. <article-title>Effects of tirofiban on neurological deterioration in patients with acute ischemic stroke: a randomized clinical trial</article-title>. <source>JAMA Neurol</source>
<year>2024</year>;<volume>81</volume>:<fpage>594</fpage>&#x02013;<lpage>602</lpage>.<pub-id pub-id-type="pmid">38648030</pub-id>
</mixed-citation></ref></ref-list></back></article>